<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703352</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2007-002605-53</org_study_id>
    <nct_id>NCT00703352</nct_id>
  </id_info>
  <brief_title>Eplerenone in Systemic Right Ventricle</brief_title>
  <acronym>EVEDES</acronym>
  <official_title>Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: There is no clinical evidence supporting medical treatment for the failing
      systemic right ventricle in patients with transposition of the great vessels with atrial
      switch. Cardiac magnetic resonance studies have shown a significant degree of myocardial
      fibrosis in right ventricles in the systemic position, which predisposes to systolic and
      diastolic dysfunction. Aldosterone is a widely recognized neurohormonal marker involved in
      the formation of myocardial fibrosis and the treatment with aldosterone antagonists has shown
      a decrease in ventricular mass in hypertensive patients, presumably related to reduction of
      myocardial fibrosis.

      HYPOTHESIS: Low dose of eplerenone, a selective mineralocorticoid receptor blocker, in
      patients with systemic right ventricle can reduce the ventricular mass by means of a
      reduction in myocardial fibrosis, resulting in improved systolic function.

      PATIENTS AND METHODS: Randomized, double blind, parallel clinical trial comparing eplerenone
      (50mg daily) with placebo.

      Study population: Adult patients (&gt;18 years) diagnosed with repaired transposition of the
      great arteries with atrial switch (Senning or Mustard techniques) routinely followed at a
      tertiary referral center.

      Duration: 12 months. Outcomes: Right ventricular mass, myocardial fibrosis mass and ejection
      fraction assessed by cardiac magnetic resonance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular mass assessed by cardiac-magnetic resonance</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular ejection fraction and myocardial fibrosis mass, assessed by cardiac magnetic resonance</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Transposition of Great Vessels</condition>
  <condition>Atrial Switch Procedure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Eplerenone (coated tablet) 50mg daily during 12 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years old)

          -  Diagnosis of transposition of the great arteries repaired with atrial switch
             procedures (Mustard or Senning).

          -  Regular follow up at tertiary referral center.

        Exclusion Criteria:

          -  Concomitant disease with life expectancy &lt;1 year.

          -  Inclusion in heart transplant waiting list.

          -  Basal serum creatinine level &gt; 1.5 mg/dl.

          -  Basal serum potassium level &gt; 5.0 mmol/L.

          -  Intolerance to the investigational medical product.

          -  Treatment with spironolactone or eplerenone within the previous 6 months.

          -  Inability to undergo magnetic resonance imaging.

          -  Pregnancy or breast feeding.

          -  Denial of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Dos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transposition of the great arteries.</keyword>
  <keyword>Transposition of the great vessels.</keyword>
  <keyword>Mustard.</keyword>
  <keyword>Senning.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

